StreetInsider.com News Articles

AngioDynamics funds Jacobi Hospital PE imaging research

Fri, 02 Oct 2026 06:03:26 -0400

AngioDynamics, Inc. (NASDAQ: ANGO) and The PERT Consortium® have selected Jacobi Hospital in the Bronx, New York, as a recipient of an ALPHA-PE Research Fund award, according to a press release from the company.

The award will fund an independent, investigator-led study by Dr. Jonathan Alis, Dr. Seth I. Sokol and their team. The study will evaluate CT pulmonary angiography radiomics as predictors of thrombus biology, thrombectomy success and long-term outcomes in patients with pulmonary embolism (PE).

The research will assess imaging biomarkers that may reflect clot composition and predict how a patient's clot responds to mechanical thrombectomy. Physicians currently have limited

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

Fri, 02 Oct 2026 06:00:00 -0400

Investigator-Led Study Will Evaluate Imaging Biomarkers That May Help Predict Thrombectomy Success and Inform Long-Term PE Care

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Dr. Jonathan Alis, Dr. Seth I. Sokol and their team at Jacobi Hospital in Bronx, New York have been selected as an ALPHA-PE Research Fund award recipients. The independent, investigator-led study, supported in partnership with The PERT Consortium®, will evaluate CT pulmonary angiography radiomics as

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

Fri, 02 Oct 2026 06:00:00 -0400

Investigator-Led Study Will Evaluate Imaging Biomarkers That May Help Predict Thrombectomy Success and Inform Long-Term PE Care

Form 10-K/A ANGIODYNAMICS INC For: May 31

Tue, 29 Sep 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260929/27122336.html

Form 10-K/A ANGIODYNAMICS INC For: May 31

Tue, 29 Sep 2026 09:14:00 -0400

si-local-file:///var/storage/secattach/20260929/27118814.html

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

Mon, 28 Sep 2026 16:30:00 -0400

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

Mon, 28 Sep 2026 16:30:00 -0400

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be

Form 4 ANGIODYNAMICS INC For: Jul 30 Filed by: Nighan Warren JR

Fri, 31 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260731/26851403.html

Form 4 ANGIODYNAMICS INC For: Jul 30 Filed by: Nighan Warren JR

Fri, 31 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260731/26851403.html

Form 144 ANGIODYNAMICS INC Filed by: Nighan Warren JR

Thu, 30 Jul 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260730/26845069.html

Form 144 ANGIODYNAMICS INC Filed by: Nighan Warren JR

Thu, 30 Jul 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260730/26845069.html

AngioDynamics to Participate in Upcoming Investor Conferences

Tue, 28 Jul 2026 08:30:00 -0400

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences:

11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Monday, August 10, 2026

Canaccord Genuity's 46th Annual Growth Conference
Presentation: Tuesday, August 11, 2026 from 3:30-3:55 PM ET
A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at